June 1, 2021 ~ Trial Site News
Indian Giant Reliance Industries Developing Niclosamide-based Drug Targeting COVID-19
Much like Ivermectin, Niclosamide is in the anthelmintic family of drugs, and recently, Indian mega-corporation Reliance Industries Ltd. announced their plans to develop a treatment targeting COVID-19. A World Health Organization (WHO) essential medicine, Nicloasamide has been in use for over half a century and, in fact, the oral version of the drug was actually used during the 2003-04 SARS outbreak. TrialSite recently reported that a Danish biotech called UNION Therapeutics was also testing a form of Niclosamide involving trials in the UK. Of interest: can the drug stop the spread of SARS-CoV-2, the virus behind COVID-19?
Back in March of this year, TrialSite showcased clinical trials sponsored by the UK government’s Department of Health and Social Care (DHSC) known as the PROTECT-V and PROTECT-CH studies. In PROTECT-V, led by the University of Cambridge, the team will test the assess if Niclosamide is in fact a SARS-CoV-2 inhibitor.